Progresses in TCM metal-based antitumour agents

Anti-Cancer Agents in Medicinal Chemistry

Volumn 10, Issue 5, 2010, Pages 412-423

  Chen, Zhen Feng ^a   Liang, Hong ^a  

^a GUANGXI NORMAL UNIVERSITY   (China)

Author keywords

Antitumour agents; Metal complexes; Traditional chinese medicine (tcm)

Indexed keywords

ALKALOID DERIVATIVE; ANTINEOPLASTIC AGENT; APIGENIN; BETA CARBOLINE; CAMPHOR DERIVATIVE; CANTHARIDIN; CHRYSIN; COUMARIN DERIVATIVE; CURCUMIN; FLAVONE DERIVATIVE; FLAVONOID; HESPERETIN; LIRIODENINE; METAL COMPLEX; MORIN; NARINGENIN; PLATINUM COMPLEX; PLUMBAGIN; PRODRUG; QUERCETIN DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CHINESE MEDICINE; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION; TESTIS CANCER;

EID: 77953778575     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871520611009050412     Document Type: Article

References (143)

1. Shibata, S. In Advances in Chinese Medicinal Materials Research, Chang, H. M.; Yeung, H. W.; Tso, W. W.; Koo, A.; Eds., World Scientific Publishing: New York, 1985, pp. 3-16.
2. Chan, K. Progresseses in traditional Chinese medicine. Trends Pharmacol. Sci., 1995, 16, 182-187.
3. Patwardhan, B.; Warude, D.; Pushpangadan, P.; Bhatt, N. Evid. Based Complement. Altern. Med., 2005, 2, 465-473.
4. Gibert, T. F. Thought on traditional Chinese medicine and its pharmacopeia. Ann. Pharm. Fr., 1998, 56, 282-285.
5. Cheng, J. T. Review: drug therapy in Chinese traditional medicine. J. Clin. Pharmacol., 2000, 40, 445-450.
6. Liu, Y. C. The Essential Book of Traditional Chinese Medicine: Theory, Clinical Practice, Columbia University Press, 1988.
7. Yin, H. Fundamentals of Chinese Medicine, CBT China Book Trading, 1992.
8. Zhou, J.; Xie, G.; Yan, X. Traditional Chinese Medicine: Molecular Structures, Natural Sources and Applications (2nd ed), Wiley & Sons, NY, 2004.
9. Rosenberg, B.; Camp, L. V.; Trosko, J. E.; Mansour, V. H. Platinum compounds: a new class of potent antitumour agents. Nature, 1969, 222, 385-386
10. Orvig, C.; Abrams, M. J. Medicinal inorganic chemistry: introduction. Chem. Rev., 1999, 99, 2201-2203.
11. Clarke, M. J.; Zhu, F.; Frasca, D. R. Non-platinum chemotherapeutic metallopharmceuticals. Chem. Rev., 1999, 99, 2511-2533.
12. Wong, E.; Giandomenico, C. M. Current status of platinum-based antitumor drugs. Chem. Rev., 1999, 99, 2451-2466.
13. Jamieson, E. R.; Lippard, S. J. Structure, recognition, and processing of cisplatin-DNA adducts. Chem. Rev., 1999, 99, 2467-2498.
14. Jung, Y.; Lippard, S. J. Direct cellular responses to platinuminduced DNA damage. Chem. Rev., 2007, 107, 1387-1407.
15. Wataru, S.; Swisher, E. M.; Karlan, B. Y.; Agarwal, M. K.; Higgins, J.; Friedman, C.; Villegas, E.; Jacquemont, C.; Farrugia, D. J.; Couch, F. J.; Nicole Urban, N.; Taniguchi, T. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature, 2008, 451, 1116-1121.
16. Zutphen, S.; Reedijk, J. Targeting platinum anti-tumour drugs: Overview of strategiesemployed to reduce systemic toxicity. Coord. Chem. Rev., 2005, 249, 2845-2853.
17. Alt, A.; Lammens, K.; Chiocchini, C.; Alfred Lammens, A.; Pieck, J. C.; Kuch, D.; Karl-Peter Hopfner, K.-P.; Carell, T. Bypass of DNA lesions generated during anticancer treatment with cisplatin by DNA polymerase eta. Science, 2007, 318, 967-970.
18. Lovejoy, K. S.; Lippard, S. J. Non-traditional platinum compounds for improved accumulation, oral bioavailability, and tumor targeting. Dalton Trans., 2009, 10651-10659.
19. Kelland, L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev., 2007, 7, 573-583.
20. Ho, Y.-P.; To, K. K. W.; Au-Yeung, S. C. F.; Wang, X.; Lin, G.; Han, X. Potential new antitumor agents from an innovative combination of demethylcantharidin, a modified traditional Chinese medicine, with a platinum moiety. J. Med. Chem., 2001, 44, 2065-2068.
21. Chen, Z.-F.; Liu, Y.-C.; Liu, L.-M.; Wang, H.-S.; Qin, S.-H.; Wang, B.-L.; Bian, H.-D.; Yang, B.; Fun, H.-K.; Liu, H.-G.; Liang, H.; Orvig, C. Potential new inorganic antitumour agents from combining the anticancer traditional Chinese medicine (TCM) liriodenine with metal ions, and DNA binding studies. Dalton Trans., 2009, 262-272.
22. Liu, Y.-C.; Chen, Z.-F.; Liu, L.-M.; Peng, Y.; Hong, X.; Yang, B.; Liu, H.-G.; Liang, H.; Orvig, C. Divalent later transition metal complexes of the traditional chinese medicine (TCM) liriodenine: coordination chemistry, cytotoxicity and DNA binding studies. Dalton Trans., 2009, 10813-10823.
23. Chen, Z.-F.; Tan, M.-X.; Liu, L.-M.; Liu, Y.-C.; Wang, H.-S.; Yang, B.; Peng, Y.; Liu, H.-G.; Liang H. and Orvig, C. Cytotoxicity of the traditional Chinese medicine (TCM) plumbagin in its copper chemistry. Dalton Trans., 2009, 10824-10833.
24. Efferth, T.; Li, P.C.H.; Konkinmalla, V.S.B.; Kiana, B. From traditional Chinese medicine to rational cancer therapy. Trends Mol. Med., 2007, 13(8), 353-361.
25. Han, J. Traditional Chinese medicine and the search for new antineoplastic drugs. J. Ethnopharm., 1988, 24, 1-17.
26. Li, X.-J.; Zhang, H.-Y. Western-medicine-validated anti-tumor agents and traditional Chinese medicine. Trends Mol. Med., 2008, 14(1), 1-2.
27. Min, L.-B. New therapeutic aspects of flavones: The anticancer properties of Scutellaria and its main active constituents Wogonin, Baicalein and Baicalin. Cancer Treatment Rev., 2009, 35, 57-68.
28. Parekh, H. S.; Liu, G.; Wei, M. Q. Anew dawn for the use of traditional Chinese medicine in cancer therapy. Mol. Cancer, 2009, 8:21, doi:10.1186/1476-4598-8-21.
29. Wang, J.-F.; Wei, D.-Q.; Chou, K.-C. Drug candidates from traditional Chinese medicine. Curr. Top. Med. Chem., 2008, 8, 1656-1665.
30. Efferth, T.; Fu, Y.-J.; Zu, Y.-G.; Schwarz, G.; Konkimalla, V. S. B.; Wink, M. Molecular target-guided tumor therapy with natural products derived from traditional Chinese medicine. Curr. Med. Chem., 2007, 14, 2024-2032.
31. Newman, D. J.; Cragg, G. G. Natural products as sources of new drugs over the last 25 years. J. Nat. Prod., 2007, 70, 461-477.
32. Pommier, Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat. Rev. Cancer, 2006, 6, 789-802.
33. Giles, G. I. and Sharma, R. P. Topoisomerase enzymes as therapeutic targets for cancer chemotherapy. Med. Chem., 2005, 1, 383-394.
34. Huang, K. C. The Pharmacology of Chinese Herbs (2nd Ed), CRC Press: Boca Raton, 1999.
35. Malmanche, N.; Maia, A.; Sunkel, C. E. The spindle assembly checkpoint: Preventing chromosome mis-segregation during mitosis and meiosis. FEBS Lett., 2006, 580, 2888-2895.
36. Duflos, A.; Kruczynski, A.; Barret, J.-M. Novel aspectes of natural and modified vinca alkaloids. Curr. Med. Chem. Anticancer Agents, 2002, 2, 55-70.
37. Zhang, C. H.; Mei, X.G.; Liu L.; Yu, L. J. Enhanced paclitaxel production induced by the combination of elicitors in cell suspension cultures of Taxus chinensis. Biotechnol. Lett., 2000, 22, 1561-1564.
38. Sarno, S.; Moro, S.; Meggio, F.; Zagotto, G.; Ben, D D.; Ghisellini, Pa.; Battistutta, R.; Zanotti, G.; and Pinna, L. A. Toward the rational design of protein kinase casein kinase-2 inhibitors. Pharmacol. Ther., 2002, 93, 159-168.
39. Huang, Q.; Lu, G.; Shen, H.-M.; Chung, M. C. M.; Ong, C. N. Anticancer properties of anthraquinones from Rhubarb. Med. Res. Rev., 2007, 27(5), 609-630.
40. Konkimalla, V. B.; Suhas, V. L.; Chandra, N. R.; Gebhart, E.; Efferth, T. Diagnosis and therapy of oral squamous cell carcinoma. Expert. Rev. Anticancer Ther., 2007, 7, 317-329.
41. Zimmermann, S. and Martens, U. M. Telomeres andtelomerase as targets for cancer therapy. Cell Mol. Life Sci., 2007, 64, 906-921.
42. Zhang, F.; Jia, Z.; Deng, Z.; Wei, Y.; Zheng, R.; Yu, L. In vitro modulation of telomerase activity, telomere length and cell cycle in MKN45 cells by verbascoside. Planta Med., 2002, 68, 115-118.
43. Guo, Q. L.; Lin, S.-S.; You, Q.-D.; Gu, H.-Y.; Yu, J.; Zhao, L.; Qia, Q.; Liang, F.; Tan, Z.; Wang, X. Inhibition of human telomerase reverse transcriptase gene expression by gambogic acid in human hepatoma. SMMC-7721 cells. Life Sci., 2006, 78, 1238-1245.
44. Kilarski, W. W.; Bikfalvi, A. Recent developments in tumor angiogenesis. Curr. Pharm. Biotechnol., 2007, 8, 3-9.
45. Irina, S. M.; Pedro, A. F.; Maria, J. R. Vascular endothelial growth factor (VEGF) inhibition-a critical review. Anticancer Agents Med. Chem., 2007, 7, 223-245.
46. Min, J. K.; Han, K. Y.; Kim, E. C.; Kim, Y. M.; Lee, S. W.; Kim O. H.; Kim, K. W.; Gho, Y. S.; Kwon, Y. G. Capsaicin inhibits in vitro and in vivo angiogenesis. Cancer Res., 2004, 64, 644-651.
47. Kok, T. W. The anti-angiogenic effect of sinomenine. Angiogenesis, 2005, 8, 3-12.
48. Efferth, T. Artemisinins target the SERCA of Plasmodium falciparum. Drug Resist. Updat., 2005, 8, 957-961.
49. Efferth, T. Molecular pharmacology and pharmacogenomics of artemisinin and its derivatives in cancer cells. Curr. Drug Targets, 2006, 7, 407-421.
50. Efferth, T. Willmar schwabe award 2006: antiplasmodial and antitumor activity of artemisinin - from bench to bedside. Planta Med., 2007, 73, 299-309.
51. Douer, D.; Tallman, M. S. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J. Clin. Oncol., 2005, 23, 2396-2410.
52. Miler, W. H.; Schipper, H. M.; Lee, J. S.; Singer, J.; Waxman, S. Mechanisms of action of arsenic trioxide. Cancer Res., 2002, 62, 3893-3903.
53. Shan, H. B.; Cai, Y.-C.; Liu, Y.; Zeng, W.-N.; Chen, H.-X.; Fan, B.-T.; Liu, X.-H.; Xu, Z.-L.; Wang, B.; Xian, L.-J. Cytotoxicity of cantharidin analogues targeting protein phosphatase 2A. Anticancer Drugs, 2006, 17, 905-911.
54. Hambley, T. W. Metal-based therapeutics. Science, 2007, 318, 1392-1393.
55. Bruneton, J. Pharmacognosie: Phytochimie Plantes Médicinales, 2ème Ed., Lavoisier Tec & Doc: Paris, 1999.
56. Chan-Bacab, M. J.; Peña-Rodríguez, L. M. Plant natural products with leishmanicidal activity. Nat. Prod. Rep., 2001, 18, 674-688
57. Lan, Y. H.; Chang, F. R.; Yu, J. H.; Yang, Y. L.; Chang Lee, Y. L.; S. J.; Wu, Y. C. Cytotoxic styrylpyrones from Goniothalamus amuyon. J. Nat. Prod., 2003, 66, 487-490.
58. Nissanka, A. P. K.; Karunaratne, V.; Bandara, B. M. R.; Kumar, V.; Nakanishi, T.; Nishi, M.; Inada, A.; Tillekeratne, L. M. V.; Wijesundara, D.S.A.; Gunatilaka, A.A.L. Antimicrobial alkaloids from Zanthoxylum tetraspermum. and caudatum. Phytochemistry, 2001, 56, 857-861
59. Bentley, K. W. β-Phenylethylamines and the isoquinoline alkaloids. Nat. Prod. Rep., 2001, 18, 148-170
60. Leitão, G. G.; Soares, S. S. V.; Barros M. Brito, T. de; Monache, F. D. Kaempferol glycosides from Siparuma apiosyc. Phytochemistry, 2000, 55, 679-682
61. Lira, G. A.; Andrade, L. M.; Florêncio, K. C.; Silva, M. S.; Barbosa-Filho, J. M.; Cunha, E. V. L. Roraimine: a bisbenzylisoquinoline alkaloid from Cissampelos sympodialis roots. Fitoterapia., 2002, 73, 356-358.
62. Lin, C. H.; Chang, G. J.; Su, M. J.; Wu, Y. C.; Teng, C. M.; Ko, F. N. Pharmacological characteristics of liriodenine, isolated from Fissistigma glaucescens, a novel muscarinic receptor antagonist in guinea-pigs. Br. J. Pharmacol., 1994, 113, 275-281.
63. Wu, Y. C.; Duh, C. Y.; Wang, S. K.; Chen, K. S.; Yang, T. H. Two new natural azafluorene alkaloids and a cytotoxic aporphine alkaloid from Polyalthia longifolia. J. Nat. Prod., 1990, 53, 1327-1331.
64. Chang, H. C.; Chang, F. R.; Wu, Y. C.; Lai, Y. H. Anticancer effect of liriodenine on human lung cancer cells. Kaohsiung J. Med. Sci., 2004, 20, 365-371.
65. Hsieh, T. J.; Liu, T. Z.; Chern, C. L.; Tsao, D. A.; Lu, F. J.; Syu, Y. H.; Hsien, P. Y.; Hu, H. S.; Chang, T. T.; Chen, C. H. Liriodenine inhibits the proliferation of human hepatoma cell lines by blocking cell cycle progressesesion and nitric oxide-mediated activation of P53 expression. Food Chem. Toxicol., 2005, 43, 1117-1126.
66. Woo, S. H.; Reynolds, M. C.; Sun, N. J.; Cassady, J. M.; Snapka, R. M. Inhibition of topoisomerase II by liriodenine. Biochem. Pharmacol., 1997, 54, 467-473.
67. Woo, S. H.; Sun, N. J.; Cassady, J. M.; Snapka, R. M. Topoisomerase II inhibition by aporphine alkaloids. Biochem. Pharmacol., 1999, 57, 1141-1145.
68. Liu, H.-G.; Qin, S.-H.; Liu, L.-M.; Wang, B.-L.; Liu, Y.-C.; Chen, Z.-F. Apoptosis-inducing effects of AgLA2 on SPC-A-1 cells and its mechanism in vitro. Chin. Pharmacol. Bull., 2008, 24, 1449-1452.
69. Liu, J. Y.; Hu, J. H.; Zhu, Q. G.; Li, F. Q.; Wang, J.; Sun, H. J. Effect of matrine on the expression of substance P receptor and inflammatory cytokines production in human skin keratinocytes and fibroblasts. Int. Immunopharmacol., 2007, 7, 816-823.
70. Zhang, L. J.; Wang, T. T.; Wen, X. M.; Wei, Y.; Peng, X. C.; Li, H.; Wei, L. Effect of matrine on HeLa cell adhesion and migration. Eur. J. Pharmacol., 2007, 563, 69-76.
71. Luo, C.; Zhu, Y. L.; Jiang, T. J.; Lu, X. Y.; Huang, J. Matrine induced gastric cancer MKN45 cells apoptosis via increasing pro-apoptotic molecules of Bcl-2 family. Toxicology, 2007, 229, 245-252.
72. Zhang, L. P.; Jiang, J. K.; Tam, J. W. O.; Zhang, Y.; Liu, X. S.; Xu, X. R.; Liu, B. Z.; He, Y. J. Effects of Matrine on proliferation and differentiation in K-562 cells. Leuk. Res., 2001, 25, 793-800.
73. Ruan, L.-P.; Chen, S.; Yu, B.-Y.; Zhu, D.-N.; Cordell, G. A.; Qiu, S. X. Prediction of human absorption of natural compounds by the non-everted rat intestinal sac model. Eur. J. Med. Chem., 2006, 41, 605-610.
74. Galasso, V.; Asaro, F.; Berti, F.; Pergolese, B.; Kovac, B.; Pichierri, F. On the molecular and electronic structure of matrine-type alkaloids. Chem. Phys., 2006, 330, 457-468.
75. Chen, Z.-F.; Mao, L.; Liu, L.-M.; Liu, Y.-C.; Peng, Y.; Hong, X.; Yang, B.; Liu, H.-G.; Liang, H. Potential new inorganic antitumour agents from combining the anticancer traditional Chinese medicine (TCM) matrine with Ga(III), Au(III), Sn(IV) ions, and DNA binding studies. [unpublish results].
76. Al-Allaf, T. A. K.; Ayoub, M. T.; Rashan, L. J. Synthesis and characterization of novel biologically active platinum(I1) and palladium(I1) complexes of some β-carboline alkaloids. J. Inorg. Biochem., 1990, 38, 47-56.
77. Al-Allaf, T. A. K.; Rashan, L. J. Synthesis and cytotoxic evaluation of the first trans-palladium(II) complex with naturally occurring alkaloid harmine. Eur. J. Med. Chem., 1998, 33, 817-820.
78. Nijveldt, R. J.; Nood, E.; Hoorn, D. E. C.; Norren, K.; Leeuwen, P. A. M. Flavonoids: a review of probable mechanisms of action and potential applications. Am. J. Clin. Nutr., 2001, 74, 418-425.
79. Narayana, K. R.; Reddy, M. S.; Chaluvadi, M. R.; Krishna, D. R. Bioflavonoids clas- sification, pharmacological, biochemical effects and therapeutic potential. Indian J. Pharmacol., 2001, 33, 2-16.
80. Nijhoff, W. A.; Bosboom, M. A.; Smidt, M. H.; Peters, W. H. M. Enhancement of rat hepatic and gastrointestinal glutathione and glutathione S-transferases by alpha-angelicalactone and flavone. Carcinogenesis, 1995, 16, 607-612.
81. Kosmider, B.; Zyner, E.; Osiecka, R.; Ochocki, J. Genotoxicity of cis-Pt(II) complex of 3-aminoflavone in comparison with cis-DDP in A549 cells evaluated by comet assay. Can. J. Physiol. Pharmacol., 2004, 82, 353-358.
82. Kosmider, B.; Zyner, E.; Osiecka, R.; Ochocki, J. Induction of apoptosis and necrosis in A549 cells by the cis-Pt(II) complex of 3- aminoflavone in comparison with cis-DDP. Mutat. Res., 2004, 563, 61-70.
83. Kosmider, B.; Osiecka, R. Flavonoid compounds: a review of anticancer properties and interactions with cis diamminedichloroplatinum(II). Drug Dev. Res., 2004, 63, 200-211.
84. Erdem, A.; Kosmider, B.; Osiecka, R.; Zyner, E.; Ochocki, J.; Ozsoz, M. Electrochemical genosensing of the interaction between the potential chemotherapeutic agent, cis-bis(3-aminoflavone) dichloroplatinum(II) and DNA in comparison with cis-DDP. J. Pharm. Biomed. Anal., 2005, 38, 645-652.
85. Kosmider, B.; Wojcik, I.; Osiecka, R.; Bartkowiak, J.; Zyner, E.; Ochocki, J.; Liberski, P. Enhanced P53 and BAX gene expression and apoptosis in A549 cells by cis-Pt(II) complex of 3- aminoflavone in comparison with cis-DDP. Invest. New Drugs, 2005, 23, 287-297.
86. Kosmider, B.; Zawlik, I.; Liberski, P. P.; Osiecka, R.; Zyner, E.; Ochocki, J.; Bartkowiak, J. Evaluation of P53 and BAX gene expression and induction of apoptosis and necrosis by the cis-Pt(II) complex of 3-aminoflavone in comparison with cisdiamminedichloroplatinum(II) (cis-DDP) in human lymphocytes. Mutat. Res., 2006, 604, 28-35.
87. Pusz, J.; Nitka, B.; Zielinska, A.; Wawer, I. Synthesis and physicochemical properties of the Al(III), Ga(III) and In(III) complexes with chrysin. Microchem. J., 2000, 65, 245-253.
88. Pusz, J.; Nitka, B. Synthesis and physicochemical properties of the complexes of Co(II), Ni(II), and Cu(II) with chrysin. Microchem. J., 1997, 56, 373-381.
89. Engelmann, M. D.; Hutcheson, R.; Cheng, I. F. Stability of ferric complexes with 3-hydroxyflavone (flavonol), 5,7-dihydroxyflavone (chrysin), and 3',4'-dihydroxyflavone. J. Agric. Food Chem., 2005, 53, 2953-2960.
90. Ansari, A. 1H NMR and spectroscopic studies of biologically active yttrium (III)-flavonoid complexes. Main Group Chem., 2008, 7, 133-145.
91. Zeng, Y.-B.; Yang, N.; Liu, W.-S.; Tang, N. Synthesis, characterization and DNA-binding properties of La(III) complex of chrysin. J. Inorg. Biochem., 2003, 97, 258-264.
92. Zhou, X.; Zheng R. Photosensitization of morin on tumor cells and its mechanism. J. Lanzhou Univ. (Nat. Sci.), 1991, 27, 101-104.
93. Alldrick, A. J.; Flynn J.; Rowland, I. R. Effects of plant-derived flavonoids and polyphenolic acids on the activity of mutagens from cooked food. Mutat. Res., 1986, 163, 225-232.
94. Zhang, Q.; Wang, L.; Liu X. Synthesis, characterization and antitumour properties of metal(II) solid complexes with morin. Trans. Met. Chem., 1996, 21, 23-27.
95. Song, Y.; Yang, P.; Yang, M.; Kang, J.; Qin, S.; Lü, B. Spectroscopic and vlotammetric studies of the cobalt(II) complex of morin bound to calf thymus DNA. Trans. Met. Chem., 2003, 28, 712-716.
96. Tripoli, E.; Guardia, M. L.; Giammanco, S.; Majo, D.D.; Giammanco, M. Citrus flavonoids: Molecular structure, biological activity and nutritional properties: A review. Food Chem., 2007, 104, 466-479.
97. Korkina, L. G. and Afanasev, I. B. Antioxidant and chelating properties of flavonoids. Adv. Pharmacol., 1997, 38, 151-163.
98. Pereira, R. M. S.; Andrades, N. E. D.; Paulino, N. Sawaya, A.C. H.; Eberlin, M. N.; Marcucci, M. C.; Favero, G. M.; Novak, E. M.; Bydlowski, S. P. Synthesis and characterization of a metal complex containing naringin and Cu, and its antioxidant, antimicrobial, anti-inflammatory and tumor cell cytotoxicity. Molecules, 2007, 12, 1352-1366.
99. So, F. V.; Guthrie, N.; Chambers, A. F.; Moussa, M.; Carroll, K. K. Inhibition of human breast cancer cell proliferation and delay of mammary tumorigenesis by flavonoids and citrus juices. Nutr. Cancer, 1996, 26, 167-181.
100. Chiang, L.-C.; Ng, L. T.; Lin, I.-C.; Kuo, P.-L.; Lin, C.-C. Antiproliferative effect of apigenin and its apoptotic induction in human Hep G2 cells. Cancer Lett., 2006, 237, 207-214.
101. Wang, B.-D.; Yang, Z.-Y.; Wang, Q.; Cai, T.-K.; Crewdson, P. Synthesis, characterization, cytotoxic activities, and DNA-binding properties of the La(III) complex with naringenin Schiff-base. Bioorg. Med. Chem., 2006, 14, 1880-1888.
102. Li, T.-R.; Yang, Z.-Y.; Wang, B.-D. Qin, D.-D. Synthesis, characterization, antioxidant activity and DNA-binding studies of two rare earth(III) complexes with naringenin-2-hydroxy benzoyl hydrazone ligand. Eur. J. Med. Chem., 2008, 43, 1688-1695
103. Li, T.-R.; Yang, Z.-Y.; Wang, B.-D. Synthesis, characterization and antioxidant activity of naringenin Schiff base and its Cu(II), Ni(II), Zn(II) complexes. Chem. Pharm. Bull., 2007, 55, 26-28.
104. Tan, M.-X.; Zhu, J.-C.; Pan, Y.M.; Chen, Z.-F.; Liang, H.; Liu, H.-G.; Wang, H.-S. Synthesis, cytotoxic activity, and DNA binding properties of copper (II) complexes with hesperetin, naringenin and apigenin. Bioinorg. Chem. Appl., 2009, doi:10.115/2009/347872.
105. Russo, A.; Acquaviva, R.; Campisi, A.; Sorrenti, V.; Di Giacomo, C.; Virgata, G.; Barcellona, M. L.; Vanella, A. Bioflavonoids as antiradicals, antioxidants and DNA cleavage protectors. Cell Biol. Toxical., 2000, 16, 91-98.
106. Zhou, J.; Wang, L.; Wang, J.; Tang, N. Antioxidative and antitumour activities of solid quercetin metal(II) complexes. Trans. Met. Chem., 2001, 26, 57-63.
107. Ferrer, E. G.; Salinas, M. V.; Correa, M. J.; Naso, L.; Barrio, D. A.; Etcheverry, S. B.; Lezama, L.; Rojo, T.; Williams, P. A. M. Synthesis, characterization, antitumoral and osteogenic activities of quercetin vanadyl(IV) complexes. J. Biol. Inorg. Chem., 2006, 11, 791-801.
108. Tan, J.; Wang, B. C.; Zhu, L. C. DNA binding, cytotoxicity, apoptotic inducing activity, and molecular modeling study of quercetin zinc(II) complex. Bioorg. Med. Chem., 2009, 17, 614-620.
109. Tan, J.; Wang, B. C.; Zhu, L. C. Hydrolytic cleavage of DNA by quercetin zinc(II) complex. Bioorg. Med. Chem. Lett., 2007, 17, 1197-1199.
110. Tan, J.; Wang, B. C.; Zhu, L. C. DNA binding and oxidative DNA damage induced by a quercetin copper(II) complex: potential mechanism of its antitumor properties. J. Biol. Inorg. Chem., 2009, 14, 727-739.
111. Kostova, I.; Momekov, G. New zirconium (IV) complexes of coumarin with cytotoxic activity. Eur. J. Med. Chem., 2006, 41, 717-726.
112. Thati, B.; Noble, A.; Creaven, B. S.; Walsh, M.; McCann, M.; Kavanagh, K.; Devereux, M.; Egan, D. A. In vitro anti-tumour and cyto-selective effects of courmarin-3-carboxylic acid and three of its hydroxylated derivatives, along with their silver-based complexes, using human epithelial carcinoma cell lines. Cancer Lett., 2007, 248, 321-331.
113. Kostova, I.; Momekov, G.; Zaharieva, M.; Karaivanova, M. Cytotoxic activity of new lanthanum (III) complexes of bis-coumarins. Eur. J. Med. Chem., 2005, 40, 542-551.
114. Kostova, I.; Manolov, I.; Momekov, G.; Tzanova, T.; Konstantinov, S.; Karaivanova, M. Cytotoxic activity of new cerium (III) complexes of bis-coumarins. Eur. J. Med. Chem., 2005, 40, 1246-1254.
115. Kostova, I.; Momekov, G.; Tzanova, T.; Karaivanova, M. Sythesis, characterization, and cytotoxic activity of new lanthanum (III) complexes of bis-coumarins. Bioinorg. Chem. Appl., 2006, Doi 10.1155/BCA?2006/25651. [Epub ahead of Print].
116. Wang, G. S. Medical uses of mylabris in ancient China and recent studies. J. Ethnopharm., 1989, 26, 147-162.
117. Li, Y. M.; Casida, J. E. Cantharidin-binding protein: identification as protein phosphatase 2A. Proc. Natl. Acad. Sci. USA, 1992, 89, 11867-11870.
118. Ho, Y.-P.; Au-Yeung, S. C. F.; To, K. K. W. Platinum-based anticancer agents: innovative design strategies and biological perspectives. Med. Res. Rev., 2003, 23, 5633-5655.
119. To, K. K. W.; Wang, X.; Yu, C.-W.; Ho, Y.-P.; Au-Yeung, S. C. F. Protein phosphatase 2A inhibition and circumvention of cisplatin cross-resistance by novel TCM-platinum anticancer agents containing demethylcantharidin. Bioorg. Med. Chem., 2004, 12, 4565-4573.
120. To, K. K. W.; Ho, Y.-P.; Au-Yeung, S. C. F. Determination of the release of hydrolyzed demethylcantharidin from novel traditional Chinese medicine-platinum compounds with anticancer activity by gas chromatography. J. Chromatogr. A, 2002, 947, 319-326.
121. To, K. K. W.; Ho, Y.-P.; Au-Yeung, S. C. F. In vitro and in vivo suppression of growth of hepatocelular carcinoma cells by novel traditional Chinese medicine-platinum anti-cancer agents. Anticancer Drugs, 2005, 16, 825-835.
122. To, K. K. W.; Au-Yeung, S. C. F.; Ho, Y.-P. Differential nephrotoxicity of cis-platin and a novel series of traditional Chinese medicine-platinum anticancer agents correlates with their chemical reactivity towards sulfur-containing nucleophiles. Anti-cancer Drugs, 2006, 17, 673-683.
123. Yu, C.-W.; Li, K. K. W.; Pang, S.-K.; Au-Yeung, S. C. F.; Ho, Y.-P. Anticancer activity of a series of platinum complexes integrating demethylcantharidin with isomers of 1, 2-diaminocyclohexane. Bioorg. Med. Chem. Lett., 2006, 16, 1686-1691.
124. Wang, X.; Au-Yeung, S. C. F.; Ho, Y.-P. Pharmacokinetics and tissue distribution of novel traditional Chinese medicine-platinum anticancer agents in rats. J. Inorg. Biochem., 2007, 101, 909-917.
125. To, K. K. W.; Ho, Y.-P.; Au-Yeung, S. C. F. Synergistic interaction between platinum-based antitumor agents and demethylcantharidin. Cancer Lett., 2005, 223, 227-237.
126. Lin, L. C.; Yang L. L.; Chou C. J. Cytotoxic naphthoquinones and plumbagic acid glucosides from Plumbago zeylanica. Phytochemistry, 2003, 62, 619-622.
127. Olagunju, J. A.; Jobil, A. A.; Oyedapo, O. O. An investigation into the biochemical basis of the observed hyperglycaemia in rats treated with ethanol root extract of plumbago zeylanica. Phytother. Res., 1999, 13, 346-348.
128. Srinivas, P.; Gopinath, G.; Banerji, A.; Dinakar, A.; Sriniva, G. Plumbagin induces reactive oxygen species, which mediate apoptosis in human cervical cancer cells. Mol. Carcinogen., 2004, 40, 201-211.
129. Aziz, M. H.; Dreckschmidt, N. E.; Verma, A. K. Plumbagin, a medicinal plant-derived naphthoquinone, is a novel inhibitor of the growth and invasion of hormone-refractory prostate cancer. Cancer Res., 2008, 68, 9024-9032.
130. Kuo, P.-L.; Hsu, Y.-L.; Cho, C.-Y. Plumbagin induces G2-M arrest and autophagy by inhibiting the AKT/mammalian target of rapamycin pathway in breast cancer cells. Mol. Cancer Ther., 2006, 5, 3209-3221.
131. Saxton, C. Natural remedy shows anticancer activity. Highlights in Chem. Sci., 2010, 01.
132. Sharma, O. P. Antioxidant activity of curcumin and related compounds. Biochem. Pharmacol., 1976, 25, 1811-1812.
133. Deodhar, S. D.; Sethi, R.; Srimal, R.C. Preliminary study on antirheumatic activity of curcumin (diferuloyl methane). Indian J. Med. Res., 1980, 71, 632-634.
134. Rao, T. S.; Basu, N.; Siddiqui, H.H. Anti-inflammatory activity of curcumin analogues. Indian J. Med. Res., 1982, 75, 574-578.
135. Srimal, R. C.; Dhawan, B.N. Pharmacology of diferuloyl methane (curcumin) a non-steroidal anti-inflammatory agent. J. Pharm. Pharmacol., 1973, 25, 447-452.
136. Arun, N.; Nalini, N. Efficacy of turmeric on blood sugar and polyol pathway in diabetic albino rats. Plant Foods Hum. Nutr., 2002, 57, 41-52.
137. Thompson, K. H.; Böhmerle, K.; Polishchuk, E.; Martins, C.; Toleikis, P.; Tse, J.; Yuen, V.; McNeill, J. H.; Orvig, C. Complementary inhibition of synoviocyte, smooth muscle cell or mouse lymphoma cell proliferation by a vanadyl curcumin complex compared to curcumin alone. J. Inorg. Biochem., 2004, 98, 2063-2070.
138. Li, S. Z. Compendium of Materia Medica; the People's Public Health Publishing Company, 1975, p. 1947.
139. Wang, L.; Gou, S.; Chen, Y., Liu, Y. Potential new antitumour agents from an innovative cmbination of camphorato, a ramification of traditional Chinese medicine, with a platinum moiety. Bioorg. Med. Chem. Lett., 2005, 15, 3417-3422.
140. Csermely, P.; Ágoston, V.; Pongor, S. The efficiency of multitarget drugs: the network approach might help drug design. Trends Pharmacol. Sci., 2005, 26, 178-182.
141. Kitano, H. A robustness-based approach to systems-oriented drug design. Nat. Rev. Drug Discov., 2007, 6, 202-210.
142. Normile, D. The new face of traditional Chinese medicine. Science, 2003, 299, 188-190.
143. Stone, R. Lifting the veil on traditional Chinese medicine. Science, 2008, 319, 709-710.